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Nanoformulated Copper/Zinc Superoxide Dismutase
Reduces Adipose Inflammation in Obesity
Curtis Perriotte-Olson1,2, Nikhil Adi1,2, Devika S. Manickam3, Rachel A. Westwood1,2, Cyrus V. Desouza1,2,
Gopalakrishnan Natarajan1,2, Alexandra Crook1,2, Alexander V. Kabanov3, and Viswanathan Saraswathi1,2
Objective: An intimate association exists between oxidative stress and inflammation. Because adipose tis-
sue (AT) inflammation is intricately linked to metabolic disorders, it was hypothesized that reducing oxida-
tive stress would be effective in ameliorating AT inflammation in obesity.
Methods: Wild-type mice were fed a high-fat diet (HF) for 8 weeks followed by a 2-week treatment with
nanoformulated copper/zinc superoxide dismutase (NanoSOD). The mice were divided into: 1) chow diet,
2) HF, and 3) HF1NanoSOD.
Results: The HF1NanoSOD-treated mice showed a significant decrease in plasma and liver triglycerides
when compared with HF-fed mice. Interestingly, NanoSOD reduced the expression of macrophage and
inflammatory markers in visceral AT (VAT) and stromal cells derived from VAT. Moreover, the activation of
proinflammatory signaling pathways, in particular, the extracellular signal-regulated kinases, was blunted
in VAT on NanoSOD treatment. However, markers of oxidative stress were not altered significantly in the
HF1NanoSOD group in the experimental conditions. Pretreatment of either macrophages or adipocytes
significantly reduced the inflammatory response invoked in an in vitro coculture system, further support-
ing the role of NanoSOD in inhibiting obesity-linked inflammation.
Conclusions: This data suggest that NanoSOD is effective not only in reducing AT macrophage accumu-
lation and AT inflammation but also in promoting triglyceride metabolism in obesity.
Obesity (2016) 24, 148–156. doi:10.1002/oby.21348
Introduction
Adipose tissue (AT) inflammation characterized by macrophage accu-
mulation and secretion of inflammatory mediators is an underlying
factor leading to obesity-linked metabolic disorders (1,2). Oxidative
stress is a prevalent condition in obesity. When obesity persists for a
prolonged period of time, antioxidant sources can be depleted,
decreasing the activity of enzymes such as superoxide dismutase
(SOD) and catalase in erythrocytes (3). The activity of SOD and gluta-
thione peroxidase in individuals with obesity is significantly lower
when compared with that in healthy persons (4). In addition to erythro-
cyte levels, AT levels of the antioxidant enzymes are reduced in obe-
sity (5). The levels of carbonylated proteins, a marker of oxidative
stress, have been shown to be increased in the subcutaneous fat in
human subjects with obesity (6). These studies indicate that oxidative
stress is closely associated with obesity and that targeting this process
may be effective in alleviating obesity-linked metabolic disorders.
Despite the strong association between oxidative stress and obesity,
there is a paucity of evidence suggesting the potential of SOD in
ameliorating obesity-associated metabolic disorders. Pires et al. (7)
have shown that treatment with MnTBAP, a MnSOD mimetic,
reduces visceral adiposity and AT inflammation. The effectiveness
of antioxidant therapy still remains questionable because of the fail-
ure in clinical trials that addressed the benefits of using antioxidant
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vitamins in treating human diseases (8,9). The lack of potent and
highly bioavailable antioxidants is considered to be a major challenge
in antioxidant therapy. With the advent of nanotechnology, research
on antioxidant enzyme therapy has gained increased momentum.
Several types of nanoformulated antioxidant enzymes, in particular,
SOD1, have been designed and studied for their efficacy in ameliorating
various diseases. For example, liposome-encapsulated Cu/ZnSOD
(SOD1) reduced angiotensin II (Ang II)-induced hypertension (10). Rose-
nbaugh et al. (11) have reported the benefits of poly(ethyleneimine)–
poly(ethylene glycol) (PEI–PEG)-conjugated Cu/ZnSOD nanozyme in
attenuating Ang II-induced pressor response in rabbits. Recently, a novel
formulation of Cu/ZnSOD was developed wherein SOD1 is covalently
stabilized and crosslinked to improve the stability and efficacy of SOD1
in vivo. Manickam et al. (12) have reported that this formulation of Cu/
ZnSOD (hereafter referred to as NanoSOD) is very effective in scaveng-
ing superoxide in cultured endothelial and neuronal cells in vitro and in
reducing ischemic brain injury in rats. In the current study, we sought to
determine the effectiveness of NanoSOD in reducing AT inflammation in
obesity. Because oxidative stress is prevalent in obesity and because
agents with antioxidant properties can reduce inflammation, we hypothe-
sized that NanoSOD will be effective in reducing AT inflammation and
systemic metabolic homeostasis in a model of diet-induced obesity.
Methods
Mice and diet
Male wild-type C57BL/6 mice were purchased from Jackson Labora-
tory and fed a chow diet (CD; #5001, Purina Laboratory Diet) or a
high-fat diet (HF; #D12451, Research Diets Inc.) for 8 weeks. The diet
provides 20% protein, 35% carbohydrates, and 45% fat in terms of
calories. Lard was used as a fat source.
NanoSOD preparation
NanoSOD was synthesized and characterized as reported earlier (12).
Briefly, native bovine Cu/ZnSOD protein (Sigma–Aldrich) was mixed
with poly(L-lysine)–poly(ethylene glycol) copolymer (PLL–PEG). The Cu/
ZnSOD and PLL–PEG complex was covalently stabilized using a reduci-
ble crosslinker, 3,30-dithiobis(sulfosuccinimidyl propionate) (Thermo
Fisher Scientific). The size of NanoSOD was estimated to be35 nm.
NanoSOD treatment
Eight weeks post-diet, the mice were divided into three groups: 1) CD, 2)
HF, and 3) HF diet1NanoSOD (HF1NanoSOD). The HF-fed mice
were weight-matched before the treatment. A cohort of HF diet-fed mice
were injected intraperitoneally (i.p.) with NanoSOD once every other day
for a period of 15 days (eight injections total). The mice were continued
on respective diets until sacrifice. Lean and fat mass were measured by
EchoMRI before sacrifice. Twenty-four hours post-injection of the last
dose of NanoSOD, the mice were sacrificed after 5-h fasting. All animal
care procedures were carried out with approval from the Institutional
Animal Care and Use Committee of VA Nebraska-Western Iowa Health
Care System.
Metabolic variables
Blood glucose was measured using the Accuchek Aviva glucometer.
Plasma free fatty acids (FFAs) were measured using a kit (Wako).
Plasma total cholesterol and triglycerides (TGs) were measured
using kits from Raichem. Plasma insulin was measured using kits
from Mercodia.
In vivo metabolic studies
A separate set of mice were used for energy expenditure and intra-
peritoneal insulin (ITT) and glucose tolerance tests (GTT). Because
of the short duration of the treatment, we measured energy expendi-
ture after two or four injections, ITT after five injections, and GTT
after seven injections of NanoSOD. For energy expenditure studies,
mice were acclimatized for 2 days and housed individually in Prom-
ethion cages (Sable Systems International). We recorded VO2,
VCO2, and food intake for 36 h. Measurements for 12-h light and
12-h dark cycles are reported separately. For ITT and GTT, mice
were fasted for 5 h and injected (i.p.) with insulin (0.75 U/kg body
weight) and glucose (1 g/kg body weight), respectively. The changes
in blood glucose levels were recorded at various time points.
Isolation of stromal vascular cells
Stromal vascular cells (SVCs) were isolated from visceral adipose
tissue (VAT) as we described earlier (13).
Real-time PCR analysis
Real-time PCR analysis was carried out using primers from Applied
Biosystems. A DDCT method was used to calculate gene expression,
and the values were normalized to 18S.
Western blot analysis
Antibodies against ERK and phospho-ERK were purchased from Cell
Signaling Technologies. Antibodies for SOD1, MCP-1, and GAPDH were
obtained from Santa Cruz Biotechnology. IRDye 680 and 800 conjugated
secondary antibodies were obtained from LI-COR Biosciences.
Histology
Liver sections were stained with hematoxylin and eosin (H&E). For
immunofluorescence, the VAT sections were incubated with anti-F4/80
primary antibody (AbD Serotec) followed by incubation with Alexa
Fluor 568 conjugated secondary antibody (Life Technologies). The sec-
tions were mounted with antifade gold containing 40,6-diamidino-2-
phenylindole (Invitrogen). The pictures were taken at 103 or 203 mag-
nification using a Nikon eclipse 80i inverted fluorescence microscope.
Antioxidant status
Antioxidants in VAT such as SOD (activity) and total glutathione
were determined using kits from Cayman Chemical. Ascorbic acid
was determined using a kit from ABCAM.
Macrophage and adipocyte coculture
Thioglycollate-elicited mouse primary peritoneal macrophages were
collected as we described previously (14). Differentiation of 3T3-L1
cells to adipocytes was performed as we reported earlier with minor
modifications (15). We obtained hypertrophic adipocytes (adipocytes
with large lipid droplets) by maintaining them in culture for 4–6 weeks
before they were used for the coculture experiments. In Experiment 1,
macrophages were pretreated with NanoSOD for 3 h followed by rins-
ing in PBS. Macrophages were then added onto adipocytes at 40,000
cells per well in 12-well culture dishes. We collected media after 24 h
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of coculture and cell lysates after 48 h. In Experiment 2, adipocytes
were pretreated with NanoSOD for 6 h followed by rinsing in PBS.
Untreated control macrophages were then added onto adipocytes, and
media and cell lysates were collected. The media were analyzed for
MCP-1 by enzyme-linked immunosorbent assay (ELISA) and cell
lysates for SOD1 content by Western blot analysis.
ELISA
MCP-1 protein in cell culture supernatant was measured by sandwich
ELISA. Briefly, diluted cell culture supernatant was added to a 96-
well plate that was coated with hamster anti-mouse MCP-1 antibody
(BD Biosciences). After careful washes, biotin-conjugated hamster
anti-mouse MCP-1 antibody was added (BD Biosciences). Next, avi-
din peroxidase was added followed by color-developing reagents.
Gas chromatography
Hepatic TGs were analyzed by gas chromatography at the Lipid
Core Laboratory of Vanderbilt University.
Statistical analysis
The results are presented as mean6 SEM. Statistical significance
was determined by one-way analysis of variance followed by Bon-
ferroni’s post hoc analysis. In experiments involving two groups, a
one-tailed Student’s t test was performed. Graph-Pad Prism software
was used to determine statistical significance (P< 0.05 was consid-
ered significant). Outliers were detected using the Grubb’s test or
box plot analysis (values6 1.5 times the interquartile range) and
were removed from the data set.
Results
Effect of NanoSOD on metabolic variables
The body weight, body weight gain, and fat mass were significantly
higher in HF and HF1NanoSOD groups when compared with CD
controls (Table 1). The weights of individual fat pads such as VAT,
subcutaneous AT, and perirenal AT were significantly higher in HF
and HF1NanoSOD groups when compared with CD controls. How-
ever, no significant difference was noted between HF and
HF1NanoSOD-treated mice. The plasma total cholesterol was
increased significantly (P< 0.0001) in both HF and HF1Nano
groups when compared with CD controls (Figure 1A). The plasma
FFAs were not altered, whereas plasma TGs were significantly
reduced (P< 0.01) in HF1Nano group (P< 0.05) when compared
with HF-fed mice (Figure 1B,C). The fasting blood glucose level was
TABLE 1 Effect of NanoSOD on metabolic parameters
Measurement n CD HF HF1Nano
Body weight (g) 20–22 26.36 0.5 34.96 0.8*** 34.26 0.8***
Body weight
gain (g)
20–22 5.36 0.3 12.56 0.7*** 12.66 0.6***
Fat mass (g) 14–16 2.356 0.13 9.696 0.6*** 9.486 0.59***
Lean mass (g) 14–16 22.56 0.7 24.26 0.7 23.56 0.5
Liver weight (g) 20–22 1.126 0.04 1.176 0.06 1.136 0.03




6–8 0.086 0.01 0.406 0.07* 0.436 0.05**
Perirenal adipose
tissue weight (g)
6–8 0.086 0.02 0.556 0.09* 0.786 0.10**
*P< 0.01.
**P< 0.001.
***P< 0.0001 vs. CD.
Values are mean6SEM for each group.
Figure 1 Effect of NanoSOD on metabolic variables in mice exhibiting diet-induced obesity. (A) Total cholesterol, (B) free fatty acids, (C)
triglycerides, (D) fasting blood glucose, (E) insulin, and (F) insulin resistance via HOMA-IR were recorded. Values are expressed as mean-
6SEM of 12–14 samples in each group. *P< 0.05, **P< 0.01, and ****P< 0.0001 vs. CD; ˆP<0.05 vs. HF. CD, chow diet; HF, high-fat
diet; Nano, NanoSOD.
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significantly increased in HF (P< 0.01) but not in HF1NanoSOD
mice when compared with CD-fed mice. The plasma insulin level
was significantly higher (P< 0.01) in HF1Nano group when com-
pared with CD controls. HOMA-IR, a measure of insulin resistance,
was significantly increased in both HF (P< 0.01) and HF1Nano-
SOD (P< 0.05)-treated mice (Figure 1D–F). ITT and GTT revealed
that the response of HF1Nano mice to acute insulin or glucose
exposure was not altered when compared with HF controls (Figure
2A,B). The analysis of energy expenditure revealed that VO2 and
VCO2 did not vary between HF and HF1Nano groups after two or
four injections with NanoSOD (Figure 2C,D). In addition, food intake
was not altered between HF and HF1Nano-treated mice (Figure
2E). Altogether, these data suggest that NanoSOD treatment for 2
weeks resulted in reduced plasma TG without improvements in glu-
cose handling.
Effect of NanoSOD on VAT inflammation
Because macrophages accumulate in AT in obesity and secrete
inflammatory mediators, we next analyzed macrophage and inflam-
matory markers in whole VAT. Immunofluorescence analysis
revealed that F4/80, a macrophage marker, is lower in HF1Nano
group when compared with HF-fed mice (Figure 3A,B). Real-time
PCR analysis of VAT for the mRNA expression of F4/80 showed a
profound increase only in HF-fed mice, whereas HF1Nano-treated
mice showed a reduction (Figure 3C). The markers of inflammation
including MCP1, TNFa, and MMP12 were significantly increased in
HF diet-fed mice when compared with CD controls, whereas treat-
ment with NanoSOD greatly reduced the expression of these genes.
We next analyzed the mRNA levels of macrophage and/or inflam-
matory markers in macrophage-rich SVCs collected from VAT. As
shown in Figure 3D, the mRNA level of F4/80 was significantly
reduced on treatment with NanoSOD when compared with HF con-
trols. Moreover, we noted that markers of inflammation such as
MIP1a and MMP12 were significantly lower in NanoSOD-treated
mice when compared with HF controls.
We also noted that the plasma level of MCP1 was significantly lower in
HF1NanoSOD-treated mice when compared with HF group (Figure 3E).
We next determined whether reduction in inflammation is associated with
an increase in SOD1 protein in HF1Nano-treated mice (Figure 3F–H).
Although the inflammatory markers were reduced, the protein level of
SOD1 was not altered significantly in VAT, SVCs, and plasma samples of
HF1Nano-treated mice. Altogether, these data show that NanoSOD
treatment is highly effective in reducing AT and systemic inflammation;
however, the protein levels of SOD1 are not altered significantly when
mice are sacrificed 24 h post-treatment.
Western blot analysis of VAT for signaling pathways activated by
oxidative stress, in particular, ERK1/2, showed that the phosphoryla-
tion of this protein was significantly increased in HF when com-
pared with CD controls. On the other hand, NanoSOD treatment
leads to a profound decrease in phospho-ERK1/2 when compared
with HF diet-fed mice (Figure 4A). However, markers of oxidative
stress/antioxidant response such as SOD activity, GSH depletion,
and ascorbate levels were not altered significantly (Figure 4B–D).
Pretreatment of macrophages or adipocytes with
NanoSOD reduces coculture-induced
inflammatory response
To determine the direct effect of NanoSOD in delivering SOD1 to
adipocytes and/or macrophages and in reducing their inflammatory
Figure 2 Effect of NanoSOD on insulin and glucose tolerance, energy expenditure, and food intake. Fasted mice
were intraperitoneally injected with (A) insulin and (B) glucose, and blood glucose was recorded at select time points.
Energy expenditure in the form of (C) VO2, and (D) VCO2 and (E) food intake was measured using a Promethion met-
abolic system. Energy expenditure was measured after two or four injections, and values are expressed as
mean6SEM of seven to eight samples in each group. Food intake was measured after four or five injections, and
values are mean6SEM of four to five samples in each group. HF, high-fat diet; Nano, NanoSOD.
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response, we performed an in vitro coculture study (16). In this
experiment, we determined the impact of preloading macrophages
versus adipocytes with NanoSOD in modulating the inflammatory
response provoked on their interaction. Our data show that pretreat-
ment of either macrophages or adipocytes with NanoSOD attenuates
coculture-induced inflammatory response as detected by MCP-1
secretion (Figure 5A,B). Our data also show that pretreatment of
macrophages did not increase cellular SOD1 content (Figure 5C)
likely due to the smaller number of macrophages added to the cocul-
ture system (40,000 cells per well). However, pretreatment of adipo-
cytes with NanoSOD leads to a significant increase in intracellular
SOD1 protein (Figure 5D). These data suggest that nanoformulation
of SOD1 actually increases the delivery of SOD1 protein to cells.
Effect of NanoSOD on hepatic lipid accumulation
Obesity is associated with excess lipid accumulation in liver leading
to hepatic steatosis. The mRNA expression of carnitine palmitoyl
transferase-1, an enzyme involved in fatty acid metabolism, was
increased only in HF diet-fed mice but not in HF1NanoSOD-
treated mice (Figure 6A). The mRNA expression of ACOX-1, an
enzyme involved in peroxisomal fatty acid metabolism, and,
SREBF1, a gene promoting lipogenesis, was not altered among dif-
ferent groups. Interestingly, the expression of fatty acid synthase
(FASN), another lipogenic enzyme involved in de novo fatty acid
synthesis, was reduced in HF1NanoSOD-treated mice when com-
pared with HF-fed mice. H&E staining of liver sections showed that
the lipid accumulation was greatly increased in HF group when
compared with CD controls. We noted a marked reduction in lipid
droplets in HF1NanoSOD-treated mice (Figure 6B–D). Moreover,
the levels of hepatic TGs were significantly reduced in HF1Nano
when compared with HF-fed mice (Figure 6E). Altogether, these
data show that NanoSOD reduces hepatic lipid accumulation and
suggest that inhibition of de novo lipogenesis in liver may be one
mechanism for reduced plasma and liver TGs in these mice.
Discussion
In the current study, we have demonstrated that treating obese mice
with NanoSOD for only 2 weeks results in attenuation of AT inflam-
mation characterized by reduction in macrophage and inflammatory
markers in VAT as well as in VAT stromal cells. This was associated
with a reduction in ERK1/2 activation, a signaling pathway activated
by both oxidative stress and inflammation. Furthermore, we provide
evidence that pretreatment of macrophages or adipocytes with Nano-
SOD can attenuate coculture-induced inflammatory response in vitro.
Figure 3 Effect of NanoSOD on VAT and systemic inflammation and SOD1 bioavailability. VAT sections from (A) HF and (B) HF1Nano
were assessed for F4/80 expression, and fluorescent images were obtained at 320 magnification. Markers of inflammation were deter-
mined in (C) VAT and (D) SVC via real-time PCR. (E) MCP1 protein levels were also analyzed in the plasma. SOD1 bioavailability was
determined in (F) VAT, (G) SVCs, and (H) plasma via Western blot analysis. All mRNA values were normalized to 18S, and protein levels
were normalized to GAPDH. Values are expressed as mean6SEM of 10–14 samples in each group. *P< 0.05, **P< 0.01, ***P< 0.001,
and ****P< 0.0001 vs. CD (all but 3D) or HF (3D); ˆP< 0.05 and ˆ ˆP< 0.01 vs. HF. CD, chow diet; HF, high-fat diet; Nano, NanoSOD.
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Our data also demonstrate that plasma and liver TG levels are reduced
on NanoSOD treatment indicating improvements in lipid homeostasis.
However, NanoSOD treatment did not alter markers of oxidative stress
in VAT in our experimental condition. Moreover, systemic glucose
homeostasis was not altered between HF and HF1NanoSOD-treated
mice. Altogether, our data suggest that NanoSOD treatment can
reduce AT inflammation and systemic and liver TG, which, in turn,
could reduce obesity-linked lipid disorders including hypertriglyceri-
demia and nonalcoholic fatty liver disease.
Evidence from animal and human studies suggest that oxidative
stress in AT may contribute to the development of inflammation
(17,18) and insulin resistance in obesity (19-21). An important find-
ing of our study is that NanoSOD treatment leads to a profound
reduction in macrophage and inflammatory markers in AT. The in
vitro coculture studies provide further evidence for the direct role of
NanoSOD in delivering SOD1 to adipocytes and/or macrophages
and reducing macrophage and/or adipocyte inflammation, which, in
turn, can reduce AT inflammation in obesity. The reduced AT mac-
rophage accumulation and AT inflammation may also be due to
improved lipid homeostasis (reduced plasma and liver TGs). This
notion is supported by a previous report showing that increased local
and circulating FFAs in obesity was associated with increased AT
macrophage accumulation (22). Therefore, it is very likely that an
improvement in systemic and local fatty acid/TG homeostasis can
also reduce AT macrophage accumulation and inflammation.
A previous study by Pires et al. (7) has shown that simultaneous
exposure of mice to HF diet and MnTBAP, a MnSOD mimetic,
reduces AT inflammation and systemic FFA levels. In line with this
study, we provide evidence that NanoSOD treatment led to a reduc-
tion in AT inflammation. Our study differs from that of Pires et al.
in several ways. First, we used nanoformulated Cu/ZnSOD, whereas
Pires et al. used a MnSOD mimetic. Next, we studied the therapeu-
tic effect of NanoSOD by first placing the mice on a HF diet fol-
lowed by treatment with NanoSOD. In their study, the preventive
effect of MnTBAP was assessed. Finally, our data show that in addi-
tion to reducing AT inflammation, NanoSOD reduced plasma and
liver TG levels. Altogether, these studies provide critical information
regarding the role of superoxide in modulating obesity-linked
inflammation and lipid metabolism.
It is interesting to note that the plasma and liver TGs were significantly
lower in HF1Nano when compared with HF-fed mice suggesting an
improved TG metabolism. The link between SOD1 and metabolism is
evident from the fact that SOD1 mutant mice with gain of function
exhibit hypermetabolism (23,24) characterized by increased TG
metabolism in muscle. Moreover, mice lacking SOD1 have been
shown to exhibit increased lipid accumulation in liver via increased
lipogenesis (25). Our data show that the expression of FASN, a lipo-
genic enzyme, is significantly reduced in liver on NanoSOD treatment.
Therefore, it is possible that similar mechanisms play a role in reduc-
ing TG levels in plasma and liver in our study.
Regarding signaling mechanisms, we noted that activation of ERK1/2
was increased in HF-fed mice, whereas NanoSOD attenuated this
effect. Evidence suggests that ERK1/2 is activated by FFAs and oxida-
tive stress ((26); reviewed in ref. 27). Moreover, bioflavonoids and tri-
terpenoids with known antioxidant properties have been shown to
attenuate inflammation via inhibiting ERK1/2 phosphorylation (28-
Figure 4 Effect of NanoSOD on VAT oxidative stress. (A) Phosphorylation of ERK1/2, as well as markers of anti-
oxidant defense such as (B) superoxide dismutase activity, (C) total glutathione, and (D) ascorbic acid, were
analyzed. P-ERK was normalized to total ERK. Values are expressed as mean6SEM of 6–14 samples in each
group. **P< 0.01 vs. CD; ˆ ˆ ˆP< 0.001 vs. HF. CD, chow diet; HF, high-fat diet; Nano, NanoSOD.
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30). ERK1/2 activation can lead to activation of NF-jB, which, in
turn, can activate the inflammatory response. We previously showed
that treatment of endothelial cells with linoleic acid, a FFA, can induce
oxidative stress and inflammatory response and that this was mediated
via ERK1/2 and NF-jB (26). Therefore, it is very likely that Nano-
SOD reduces inflammatory response via blunting ERK1/2 activation.
Despite the promising effects seen with regard to AT inflammation
and lipid homeostasis in HF1Nano-treated mice, we were not able
to show a change in markers of oxidative stress in these mice. One
possible reason for this could be our experimental condition. For
example, we sacrificed mice 24 h after injecting the last dose of
NanoSOD. It is possible that NanoSOD was effective in the initial
hours and then removed from the system likely via proteolytic deg-
radation. However, the effectiveness of NanoSOD in scavenging
superoxide is evident from previous studies. For example, NanoSOD
reduced superoxide-induced oxidative stress in cultured endothelial
and neuronal cells in vitro (12). Moreover, our in vitro data provide
evidence that NanoSOD is effective in increasing SOD1 protein in
adipocytes. Therefore, it is possible that improvements seen in AT
inflammation and metabolic markers in our study could be due to
improved superoxide-scavenging effects of NanoSOD. However,
further time course studies will be required to confirm this notion
in vivo.
It should be pointed out that clinical trials in humans did not support
the benefit of antioxidant therapy against cardiovascular disease
(reviewed in ref. 8). The failure of these trials could be due to the
Figure 5 Effect of NanoSOD on inflammatory response in adipocyte and macrophage cocultures. MCP1 secretion by
(A) adipocytes cocultured with NanoSOD-pretreated macrophages (Nano-mac) and (B) NanoSOD-pretreated adipo-
cytes (Nano-AD) cocultured with macrophages. MCP-1 levels in coculture media samples at 24 h were analyzed by
ELISA. Cell lysates from adipocytes cocultured with (C) NanoSOD-pretreated macrophages and (D) NanoSOD-pre-
treated adipocytes cocultured with control macrophages for 48 h were analyzed for intracellular SOD1 levels by West-
ern blotting. Values are expressed as mean6SEM of 6–12 samples for ELISA (A and B) and 3–6 samples for Western
blot (C and D) in each group. Protein was normalized to GAPDH. *P< 0.05, **P<0.01, and ****P< 0.0001 vs. AD;
^^^^P<0.0001 vs. AD1Cont-Mac; ###P< 0.01 vs. Cont-AD1Mac. AD, adipocytes; AD1Cont-Mac, adipocytes
with nontreated macrophages; AD1Nano-Mac, adipocytes with NanoSOD-treated macrophages; Cont-AD1Mac,
nontreated adipocytes with macrophages; Nano-AD1Mac, NanoSOD-treated adipocytes with macrophages.
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choice of the antioxidants and the endpoints. For example, mostly
vitamins were used as antioxidants, and vitamin E, in particular, can
exert prooxidant effects under certain conditions (31,32). Moreover,
although the role of antioxidant vitamins on cardiovascular disease
and cancer has been studied in humans, not much is known regard-
ing their effects on metabolic pathways. Our findings are relevant to
human diseases in two ways. First, our findings have implications in
considering NanoSOD as a novel therapy to target AT inflammation
and lipid disorders in obesity. Second, patients with amyotropic lat-
eral sclerosis (ALS) with increased SOD activity exhibit hyperme-
tabolism, and a high-caloric diet may improve their energy balance
and survival (33,34). Our data suggest the role of reduced de novo
fatty acid synthesis as a potential mechanism for improved energy
balance in patients with ALS on a high-caloric diet. Overall, our
study provides a better understanding on the role of NanoSOD in reduc-
ing AT inflammation and improving lipid homeostasis in obesity.O
Figure 6 Effect of NanoSOD on genes modulating fatty acid metabolism and hepatic steatosis. (A) Markers of
fatty acid metabolism were assessed in liver samples by real-time PCR. Hepatic lipid accumulation in (B) CD,
(C) HF, and (D) HF1Nano was analyzed using hematoxylin and eosin staining, whereas (E) hepatic triglycer-
ides were determined using gas chromatography. All mRNA values were normalized to 18S. Values are
expressed as mean6SEM of 10–14 samples in each group. *P< 0.05 and **P< 0.01 vs. CD; ˆP< 0.05 vs.
HF. CD, chow diet; HF, high-fat diet; Nano, NanoSOD.
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